Bivatuzumab
Bivatuzumab (previously BIWA 4) is a humanized monoclonal antibody against CD44 v6.
It is officially described as "immunoglobulin G1 (human-mouse monoclonal BIWA4 γ1-chain anti-human antigen CD44v6), disulfide with human-mouse monoclonal BIWA4 κ-chain, dimer". Prior to 2002 it was described as targeting CD44 v8.